Is there a delay in the antidepressant effect? A meta-analysis

被引:188
作者
Posternak, MA [1 ]
Zimmerman, M [1 ]
机构
[1] Brown Univ, Rhode Isl Hosp, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02905 USA
关键词
D O I
10.4088/JCP.v66n0201
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objectives: It has long been thought that there is a delay of several weeks before a true antidepressant effect occurs, although this theory has increasingly come into question. The goals of this meta-analysis were to determine whether significant drug-placebo separation occurs during the first 2 weeks of treatment and to ascertain whether the timing of response to antidepressant medication and placebo is distinct. Data Sources: Seventy-six double-blind, placebo-controlled trials conducted between 1981 and 2000, included in a recently published meta-analysis that evaluated placebo response rates in depressed outpatients, were reviewed. In addition, each issue of 6 psychiatric journals from January 1992 through December 2001 was reviewed. Study Selection: Forty-seven studies that evaluated antidepressant medications with established efficacy, performed weekly or biweekly (every other week) evaluations, and presented the time course of improvement as measured by the Hamilton Rating Scale for Depression were included in our meta-analysis. Data Synthesis: The time course of improvement on active medication and placebo was nearly identical, as 60.2% and 61.6% of the improvement that occurred on active medication and placebo, respectively, took place during the first 2 weeks of treatment. Drug-placebo differences were not only present but were most pronounced during the first 2 weeks of treatment and diminished in a stepwise fashion thereafter. A series of subanalyses confirmed that this early drug-placebo separation was clinically observable and represented a true drug effect. Conclusion: These results challenge the notion that a delay exists before a true antidepressant effect occurs.
引用
收藏
页码:148 / 158
页数:11
相关论文
共 145 条
[11]  
BYERLEY WF, 1988, J CLIN PSYCHOPHARM, V8, P112
[12]   A CANADIAN MULTICENTER PLACEBO-CONTROLLED STUDY OF A FIXED-DOSE OF BROFAROMINE, A REVERSIBLE SELECTIVE MAO-A INHIBITOR, IN THE TREATMENT OF MAJOR DEPRESSION [J].
CHOUINARD, G ;
SAXENA, BM ;
NAIR, NPV ;
KUTCHER, SP ;
BAKISH, D ;
BRADWEJN, J ;
KENNEDY, SH ;
SHARMA, V ;
REMICK, RA ;
KUKHAMOHAMAD, SA ;
BELANGER, MC ;
SNAITH, J ;
BEAUCLAIR, L ;
POHLMANN, H ;
DSOUZA, J .
JOURNAL OF AFFECTIVE DISORDERS, 1994, 32 (02) :105-114
[13]   A DOUBLE-BLIND EVALUATION OF ZIMELIDINE IN COMPARISON TO PLACEBO AND AMITRIPTYLINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER [J].
CLAGHORN, J ;
GERSHON, S ;
GOLDSTEIN, BJ ;
BEHRNETZ, S ;
BUSH, DF ;
HUITFELDT, B .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1983, 7 (2-3) :367-382
[14]   A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ORG-3770 IN DEPRESSED OUTPATIENTS [J].
CLAGHORN, JL ;
LESEM, MD .
JOURNAL OF AFFECTIVE DISORDERS, 1995, 34 (03) :165-171
[15]   Fluvoxamine maleate in the treatment of depression: A single-center, double-blind, placebo-controlled comparison with imipramine in outpatients [J].
Claghorn, JL ;
Earl, CQ ;
Walczak, DD ;
Stoner, KA ;
Wong, LF ;
Kanter, D ;
Houser, VP .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (02) :113-120
[16]  
CLAGHORN JL, 1992, J CLIN PSYCHIAT, V53, P434
[17]  
Cohn CK, 1996, J CLIN PSYCHIAT, V57, P15
[18]   A COMPARISON OF FLUOXETINE IMIPRAMINE AND PLACEBO IN PATIENTS WITH BIPOLAR DEPRESSIVE DISORDER [J].
COHN, JB ;
COLLINS, G ;
ASHBROOK, E ;
WERNICKE, JF .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1989, 4 (04) :313-322
[19]  
COHN JB, 1992, J CLIN PSYCHIAT, V53, P52
[20]  
COHN JB, 1985, J CLIN PSYCHIAT, V46, P26